针对抗HBV活动的fthalazine衍生物的结构优化,以改善口服生物可用性
Yurong Yang1, Fuling Xiao2, Jianping Zuo2
1State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 ZuChongZhi Road, Shanghai 201203, China; School of Chinese Materia Medica, College of Pharmacy, Nanjing University of Chinese Medicine, No. 138 Xianlin Road, Nanjing 210023, China.
研究人员开发了一种新的甲衍生物,2p化合物,用于治疗乙型肝炎病毒 (HBV) 感染. 这种新型药物表现出强大的抗病毒活性和改善的口服生物可用性,为HBV提供了一个有前途的治疗候选者.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 病毒学 病毒学
- 药用化学 医学化学
背景情况:
- 乙型肝炎病毒 (HBV) 囊蛋白对病毒复制至关重要.
- 调节HBV囊组件是一个可行的治疗策略.
- 他衍生物,如Yhhu6517,表现出强大的HBV囊组合调节 (CAM) 活性.
研究的目的:
- 为了克服Yhhu6517的口服药理动力学 (PK) 差,这是由快速的第一通代谢引起的.
- 通过提高代谢稳定性,同时保持抗病毒功效,优化HBV CAM.
- 为了确定一个临床翻译的抗HBV药物.
主要方法:
- 进行了以代谢稳定为指导的结构-活性关系 (SAR) 研究.
- 系统地用替代性水友性部分取代初级酒精组.
- 评估了体外抗病毒活性和体内药理动力学参数.
主要成果:
- 确定了具有优化水友群的化合物2p.
- 2p表现出强大的抗HBV活性 (IC50 = 0.016μM).
- 在小鼠中观察到改善的口服生物可用性 (F = 80.6%) 和增加的血暴露 (AUC0-24h = 10.3 μg·h/mL).
结论:
- 基于他的CAMs对HBV有效.
- 化合物2p表现出有希望的疗效和药理动力学特性.
- 2p代表了进一步HBV治疗开发的潜在候选药物.
更多相关视频
08:56Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
Published on: November 30, 2022
06:34Synthesis of Antiviral Tetrahydrocarbazole Derivatives by Photochemical and Acid-catalyzed C-H Functionalization via Intermediate Peroxides CHIPS
Published on: June 20, 2014
相关概念视频
Drug Biotransformation: Overview
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Factors Influencing Drug Absorption: Presystemic Elimination
ortho–para-Directing Activators: –CH3, –OH, –⁠NH2, –OCH3
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
Prodrugs
Prodrugs help overcome...
